AHR antagonist 5
Modify Date: 2024-01-12 21:44:25
AHR antagonist 5 structure
|
Common Name | AHR antagonist 5 | ||
|---|---|---|---|---|
| CAS Number | 2247953-39-3 | Molecular Weight | 550.89 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H27Cl3FN7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AHR antagonist 5AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1[1]. |
| Name | AHR antagonist 5 |
|---|
| Description | AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone[1]. Animal Model: Balb/c Mice (Mouse Colorectal Cancer Model CT26)[1] Dosage: 10 mg/kg (combination with anti-PD-1) Administration: P.o.; every day for 3 weeks Result: Significantly inhibited tumor growth inhibition. |
| References |
[1]. Alfredo C. Castro, et al. Indole ahr inhibitors and uses thereof. WO2018195397A2. |
| Molecular Formula | C25H27Cl3FN7 |
|---|---|
| Molecular Weight | 550.89 |